Omalizumab  	Omalizumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
severe  	severe  	 JJ	O
persistent  	persistent  	 JJ	O
allergic  	allergic  	 JJ	B-NP
asthma  	asthma  	 NN	I-NP
in  	in  	 IN	O
children  	children  	 NNS	O
aged  	aged  	 VBN	O
6-11  	6-11  	 CD	O
years  	years  	 NNS	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
report  	report  	 NN	I-NP
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
omalizumab  	omalizumab  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
severe  	severe  	 JJ	O
persistent  	persistent  	 JJ	O
asthma  	asthma  	 NN	B-NP
in  	in  	 IN	O
children  	children  	 NNS	O
aged  	aged  	 VBN	O
6-11  	6-11  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
submission  	submission  	 NN	I-NP
from  	from  	 IN	O
Novartis  	Novartis  	 NNP	B-NP
Pharmaceutical  	Pharmaceutical  	 NNP	I-NP
UK  	UK  	 NNP	I-NP
Ltd  	Ltd  	 NNP	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
was  	was  	 VBD	O
generally  	generally  	 RB	O
considered  	considered  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
of  	of  	 IN	O
good  	good  	 JJ	O
quality 	quality 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission  	submission  	 NN	O
was  	was  	 VBD	O
based  	based  	 VBN	O
primarily  	primarily  	 RB	O
on  	on  	 IN	O
a  	a  	 DT	O
preplanned  	preplanned  	 FW	B-NP
subgroup  	subgroup  	 FW	I-NP
IA-05  	IA-05  	 FW	I-NP
EUP  	EUP  	 FW	I-NP
( 	( 	 -LRB-	O
European  	European  	 NNP	B-NP
Union  	Union  	 NNP	I-NP
Population 	Population 	 NNP	I-NP
)  	)  	 -RRB-	O
from  	from  	 IN	O
the  	the  	 DT	O
IA-05  	IA-05  	 JJ	B-NP
trial 	trial 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
outcomes  	outcomes  	 NNS	O
including  	including  	 VBG	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
clinically  	clinically  	 JJ	B-NP
significant  	significant  	 JJ	I-NP
( 	( 	 -LRB-	O
CS 	CS 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
clinically  	clinically  	 RB	B-NP
significant  	significant  	 JJ	I-NP
severe  	severe  	 JJ	I-NP
( 	( 	 -LRB-	O
CSS 	CSS 	 NNP	B-NP
)  	)  	 -RRB-	O
exacerbations 	exacerbations 	 NN	B-NP
.  	.  	 .	O
Omalizumab  	Omalizumab  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
rate  	rate  	 NN	O
of  	of  	 IN	O
CS  	CS  	 NNP	B-NP
exacerbations 	exacerbations 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
rate  	rate  	 NN	O
of  	of  	 IN	O
CSS  	CSS  	 NNP	B-NP
exacerbations  	exacerbations  	 NN	I-NP
was  	was  	 VBD	O
not  	not  	 RB	O
statistically  	statistically  	 RB	O
significant 	significant 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
benefit  	benefit  	 NN	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
CS  	CS  	 NNP	B-NP
exacerbations  	exacerbations  	 NN	I-NP
was  	was  	 VBD	O
achieved  	achieved  	 VBN	O
mainly  	mainly  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
more  	more  	 JJR	O
than  	than  	 IN	O
three  	three  	 CD	O
exacerbations  	exacerbations  	 NN	B-NP
per  	per  	 IN	O
year  	year  	 NN	O
at  	at  	 IN	O
baseline 	baseline 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
found  	found  	 VBD	O
no  	no  	 DT	O
previous  	previous  	 JJ	O
published  	published  	 VBN	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
studies  	studies  	 NNS	I-NP
of  	of  	 IN	I-NP
omalizumab  	omalizumab  	 NN	I-NP
in  	in  	 IN	O
children  	children  	 NNS	O
aged  	aged  	 VBN	O
6-11  	6-11  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
so  	so  	 IN	O
their  	their  	 PRP$	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
economic  	economic  	 JJ	I-NP
evaluation  	evaluation  	 NN	I-NP
formed  	formed  	 VBD	O
the  	the  	 DT	O
basis  	basis  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
submitted  	submitted  	 VBN	O
economic  	economic  	 JJ	B-NP
evidence 	evidence 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
economic  	economic  	 JJ	B-NP
model  	model  	 NN	I-NP
was  	was  	 VBD	O
considered  	considered  	 VBN	O
appropriate  	appropriate  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
decision  	decision  	 NN	B-NP
problem 	problem 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
from  	from  	 IN	O
the  	the  	 DT	O
model  	model  	 NN	O
indicated  	indicated  	 VBD	O
that  	that  	 DT	O
omalizumab  	omalizumab  	 NN	B-NP
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
standard  	standard  	 JJ	O
therapy  	therapy  	 NN	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
standard  	standard  	 JJ	O
therapy  	therapy  	 NN	O
alone  	alone  	 RB	O
did  	did  	 VBD	O
not  	not  	 RB	O
appear  	appear  	 VB	O
cost-effective  	cost-effective  	 JJ	O
in  	in  	 IN	O
either  	either  	 RB	O
the  	the  	 DT	O
overall  	overall  	 JJ	O
population  	population  	 NN	O
or  	or  	 CC	O
a  	a  	 DT	O
subgroup  	subgroup  	 NN	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
hospitalised  	hospitalised  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
year  	year  	 NN	B-NP
prior  	prior  	 RB	I-NP
to  	to  	 TO	O
enrollment 	enrollment 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratios  	ratios  	 NNS	I-NP
of  	of  	 IN	O
£  	£  	 NNP	O
91,169  	91,169  	 NNP	O
and  	and  	 CC	O
£  	£  	 CD	O
65,911  	65,911  	 CD	O
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	O
life-year 	life-year 	 NN	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
These  	These  	 DT	O
findings  	findings  	 NNS	O
were  	were  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
robust  	robust  	 JJ	O
across  	across  	 IN	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
range  	range  	 NN	O
of  	of  	 IN	O
alternative  	alternative  	 JJ	O
assumptions  	assumptions  	 NNS	O
through  	through  	 IN	O
one-way  	one-way  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analyses 	analyses 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
guidance  	guidance  	 NN	O
issued  	issued  	 VBN	O
by  	by  	 IN	O
NICE  	NICE  	 NNP	O
states  	states  	 NNS	O
that  	that  	 IN	O
omalizumab  	omalizumab  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
recommended  	recommended  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
severe  	severe  	 JJ	O
persistent  	persistent  	 JJ	O
allergic  	allergic  	 JJ	B-NP
asthma  	asthma  	 NN	I-NP
in  	in  	 IN	O
children  	children  	 NNS	O
aged  	aged  	 VBN	O
6-11  	6-11  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
